Introduction {#s001}
============

T[he occurrence of cardiovascular disease]{.smallcaps} (CVD) is multifactorial and major risk factors are type 2 diabetes, hypertension, smoking, overweight, dyslipidemia ([@B45]). In this context, the generation of reactive oxygen species (ROS), which is important in both normal physiology and in the pathogenesis of many diseases, seems to play a relevant role also in CVD development ([@B5]). In physiological conditions, ROS are scavenged by the antioxidant system, but when their concentration is too high, an oxidative damage to proteins, lipids, and DNA occurs ([@B39]). DNA damages are usually repaired by a specific system and the oxidized products are excreted in urine ([@B38]) without further metabolism. Increased urinary levels of the oxidized metabolites were associated with an increased risk of several pathological conditions ([@B8]). One of the most widely studied metabolite is 8-hydroxy-2-deoxyguanosine (8-OHdG), which is considered as a biomarker of oxidative damage of DNA ([@B4], [@B18]) because guanosine is the most oxidized among the DNA nucleobases. High levels of 8-OHdG have been found in fragments of aorta from patients with severe atherosclerotic lesions. In addition, 8-OHdG levels have been correlated with the number of vessels involved by the atherosclerotic process ([@B29], [@B46]). The relationship between 8-OHdG and atherogenic risk factors has been extensively studied ([@B10]). For example, 8-OHdG concentrations were higher in patients with diabetes ([@B36]) and hypertension ([@B33]). Even if published studies have shown that DNA damage is significantly associated with the development of atherosclerosis ([@B1], [@B34]), the exact role of this damage in the onset and progression of this pathology is not fully understood and the association of oxidative damage to DNA with CVD still needs to be more extensively investigated. For this reason, we performed a systematic review and meta-analysis of literature to investigate the association among 8-OHdG levels and CVD.

Methods {#s002}
=======

A protocol for this review was prospectively developed, detailing the specific objectives, the criteria for study selection, the approach to assess study quality, the outcomes, and the statistical methods.

Search strategy {#s003}
---------------

To identify all available studies, a detailed search pertaining to 8-OHdG levels and CVD was conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines ([@B27]). A systematic search was performed in the electronic databases (PubMed, Web of Science, Scopus, EMBASE), using the following search terms in all possible combinations: *8-hydroxy-2-deoxyguanosine, 8-hydroxy-2-deoxy guanosine, 8-OHdG OR 8OHdG, 8-OH-dG, 8-OHG, 8-oxo-G, 8-oxo-dG, 8-hydroxydeoxyguanosine, 8-oxo-guanine, 8-hydroxy-2-deoxyguanosine OR 8-hydroxyguanine, 8-hydroxyguanosine, 8-oxo-2-deoxyguanosine, 8-oxo-7,8-dihydro-2-deoxyguanosine, coronary artery disease, atherosclerosis, ischaemic heart disease, stroke, myocardial infarction, cardiovascular disease, coronary artery disease*. The last search was performed on November 11, 2015. The search strategy was developed without any language or publication year restriction.

In addition, the reference lists of all retrieved articles were manually reviewed. In case of missing data, study authors were contacted by e-mail to try to retrieve original data. Two independent authors (A.D.M. and M.N.D.D.M) analyzed each article and performed the data extraction independently. In case of disagreement, a third investigator was consulted (L.T.). Discrepancies were resolved by consensus. Selection results showed a high inter-reader agreement (κ = 0.96) and have been reported according to PRISMA flowchart ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}; Supplementary Data are available online at [www.liebertpub.com/ars](www.liebertpub.com/ars)).

Data extraction and quality assessment {#s004}
--------------------------------------

According to the prespecified protocol, all studies evaluating 8-OHdG levels in CVD patients were included. Case reports, reviews, and animal studies were excluded. To be included in the analysis, a study had to provide levels of 8-OHdG in CVD patients (coronary artery disease \[CAD\], stroke, peripheral artery disease, and carotid atherosclerosis) and controls. To allow for a pooled analysis of data, studies dosing 8-OHdG levels on samples different from urine or blood (*i.e.*, histological samples), lacking a control group, including a study population with a clinical condition other than CAD, stroke, peripheral artery disease, and carotid atherosclerosis, were excluded from the analysis.

In each study, data regarding sample size, major clinical and demographic variables of patients and controls, and type of 8-OHdG measurement (enzyme-linked immunosorbent assay \[ELISA\] or mass spectrometry \[MS\]) were extracted. Formal quality score adjudication was not used since previous investigations failed to demonstrate its usefulness ([@B17]).

Statistical analyses and risk of bias assessment {#s005}
------------------------------------------------

Statistical analysis was carried out using the Review Manager software (Version 5.2; The Cochrane Collaboration, Copenhagen, Denmark). Because of the heterogeneity in the methods used for measuring 8-OHdG in included studies, differences among cases and controls were expressed as standard mean difference (SMD) with pertinent 95% confidence interval (95% CI). According to widely accepted guidelines, SMD is considered small if ranging from 0.2 to 0.5, medium if 0.5--0.8, and large if \>0.8. ([@B9]) When separately assessing studies in which 8-OHdG levels were evaluated in urine and blood, differences among cases and controls were expressed as mean difference (MD) with 95% CI. The overall effect was tested using Z scores and significance was set at *p* \< 0.05. Statistical heterogeneity between studies was assessed with chi-square Cochran\'s Q test and with *I*^2^ statistic, which measures the inconsistency across study results and describes the proportion of total variation in study estimates that is due to heterogeneity rather than sampling error. In detail, *I*^2^ values of 0% indicate no heterogeneity, 25% low, 25--50% moderate, and 50% high heterogeneity ([@B12]). Publication bias was assessed by the Egger\'s test and represented graphically by funnel plots of the standard difference in means *versus* the standard error. Visual inspection of funnel plot asymmetry was performed to address for possible small-study effect, and Egger\'s test was used to assess publication bias, over and above any subjective evaluation. A value of *p* \< 0.10 was considered statistically significant ([@B41]). In case of a significant publication bias, Duval and Tweedie\'s trim and fill method was used to allow for the estimation of an adjusted effect size ([@B6]). To be as conservative as possible, the random-effect method was used for all analyses to take into account the variability among included studies.

Sensitivity analyses {#s006}
--------------------

In the frame of a sensitivity analysis, results have been stratified according to the type of vascular disease (CAD, stroke, peripheral artery disease, and carotid atherosclerosis) and study design (prospective or retrospective). Given the potential influence of type of 8-OHdG measurement on the overall effect size, we planned to perform separate analyses for studies using ELISA and those using MS. Moreover, we separately analyzed studies dosing 8-OHdG on urine and studies dosing 8-OHdG on blood samples.

Metaregression analyses {#s007}
-----------------------

We hypothesized that differences among included studies may be affected by demographic variables (mean age, male gender) and coexistence of traditional cardiovascular risk factors (hypertension, smoking habit, diabetes mellitus, obesity, hyperlipidemia). To assess the possible effect of such variables in explaining different results observed across studies, we planned to perform metaregression analyses after implementing a regression model with 8-OHdG levels as dependent variables (*y*) and the abovementioned covariates as independent variables (*x*). This analysis was performed with Comprehensive Meta-analysis (Version 2; Biostat, Englewood, NJ).

Results {#s008}
=======

After excluding duplicate results, the search retrieved 877 articles. Of these studies, 847 were excluded because they were off the topic after scanning the title and/or the abstract and because they were reviews/comments/case reports or they lacked data of interest. A total of 16 studies were excluded after full-length article evaluation ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

Thus, 14 studies ([@B2], [@B3], [@B5], [@B13], [@B15], [@B16], [@B21], [@B24], [@B25], [@B28], [@B30], [@B35], [@B37], [@B46]) on 810 CVD patients and 1106 controls were included in the final analysis ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). In detail, three studies on stroke (245 cases and 566 controls) ([@B5], [@B24], [@B37]), seven on CAD (351 cases and 404 controls) ([@B2], [@B3], [@B13], [@B21], [@B28], [@B30], [@B46]), two on patients with carotid atherosclerosis undergoing carotid endarterectomy (134 cases and 66 controls) ([@B16], [@B35]), and two on peripheral artery disease (80 cases and 70 controls) ([@B15], [@B25]) were included.

Study characteristics {#s009}
---------------------

Major characteristics of included studies are shown in [Table 1](#T1){ref-type="table"}. A total of five studies ([@B3], [@B15], [@B16], [@B24], [@B37]) were case--control studies and nine ([@B2], [@B5], [@B13], [@B21], [@B25], [@B28], [@B30], [@B35], [@B46]) had a prospective design. In 11 studies, an ELISA was used to perform 8-OHdG level assessment ([@B2], [@B3], [@B5], [@B13], [@B15], [@B21], [@B25], [@B28], [@B30], [@B37], [@B46]), and in 3 studies, liquid or gas chromatography MS ([@B16], [@B24], [@B35]). As to the type of sample, in eight studies (464 CVD patients and 376 controls), 8-OHdG levels were assessed in urinary samples ([@B2], [@B15], [@B16], [@B21], [@B24], [@B28], [@B35], [@B37]), and in six studies (346 CVD patients and 730 controls), blood samples were used ([@B3], [@B5], [@B13], [@B25], [@B30], [@B46]).

###### 

[Characteristics of Included Studies]{.smallcaps}

  *Author*                       *Study design*   *Type of CVD*   *8-OHdG measurement*   *Cases (*n*)*   *Controls (*n*)*   *Age (years)*   *Males (%)*   *Diabetes (%)*   *Hypertension (%)*   *Dyslipidemia (%)*   *Smoking (%)*   *BMI (kg/m^2^)*
  ------------------------------ ---------------- --------------- ---------------------- --------------- ------------------ --------------- ------------- ---------------- -------------------- -------------------- --------------- -----------------
  Arao *et al.* ([@B2])          Prospective      CAD             Urine (ELISA)          16              6                  61.5            100.0         40.9             45.5                 40.9                 ---             23.1
  Arca *et al.* ([@B3])          Case--control    CAD             Blood (ELISA)          86              151                59.1            82.6          15.6             49.5                 34.1                 45.3            26.6
  Brea *et al.* ([@B5])          Prospective      Stroke          Blood (ELISA)          68              409                71.0            69.4          36.0             72.0                 44.8                 29.2            ---
  Himmetoglu *et al.* ([@B13])   Prospective      CAD             Blood (ELISA)          28              27                 ---             ---           ---              ---                  ---                  ---             ---
  Idei *et al.* ([@B15])         Case--control    PAD             Urine (ELISA)          40              30                 55.0            71.0          14.0             16.5                 10.0                 ---             23.4
  Jaruga *et al.* ([@B16])       Case--control    CEA             Urine (LC-MS)          22              22                 ---             ---           ---              ---                  ---                  ---             ---
  Kim *et al.* ([@B21])          Prospective      CAD             Urine (ELISA)          35              69                 59.7            51.7          12.4             44.5                 ---                  25.0            25.2
  Lin *et al.* ([@B24])          Case--control    Stroke          Urine (LC-MS)          131             131                65.0            66.0          21.5             54.5                 ---                  47.0            23.1
  Loffredo *et al.* ([@B25])     Prospective      PAD             Blood (ELISA)          40              40                 64.5            76.2          16.2             62.5                 46.2                 ---             ---
  Nagayoshi *et al.* ([@B28])    Prospective      CAD             Urine (ELISA)          62              48                 63.1            72.4          28.6             57.3                 53.4                 46.0            ---
  Najar *et al.* ([@B30])        Prospective      CAD             Blood (ELISA)          50              50                 ---             63.0          19.0             68.0                 66.0                 24.0            ---
  Rozalski *et al.* ([@B35])     Prospective      CEA             Urine (GC-MS)          112             44                 62.9            62.0          19.2             67.5                 ---                  ---             27.0
  Shi *et al.* ([@B37])          Case--control    Stroke          Urine (ELISA)          46              26                 61.7            65.3          12.5             63.9                 ---                  ---             ---
  Xiang *et al.* ([@B46])        Prospective      CAD             Blood (ELISA)          74              53                 60.8            55.9          28.3             68.5                 47.2                 27.6            ---

8-OHdG, 8-hydroxy-2-deoxyguanosine; BMI, body--mass index; CAD, coronary artery disease; CEA, carotid endarterectomy; ELISA, enzyme-linked immunosorbent assay; GC-MS, gas chromatography--mass spectrometry; LC-MS, liquid chromatography--mass spectrometry; PAD, peripheral artery disease.

The number of patients varied from 16 to 131, the mean age from 55 to 71 years, and the prevalence of male gender from 51.7% to 100%. The presence of hypertension was reported by 16.5%--72.0% of patients, smoking habit by 24%--47%, diabetes mellitus by 12.4%--40.9%, and dyslipidemia by 10%--53.4%. Mean body--mass index (BMI) varied from 23.1 kg/m^2^ to 27.0 kg/m^2^.

In the 14 studies, we found that 810 CVD patients showed significantly higher 8-OHdG levels than the 1106 controls (SMD: 1.04, 95% CI: 0.61--1.47, *p* \< 0.00001, *I*^2^ = 94%, *p* \< 0.00001). As shown in [Figure 1](#f1){ref-type="fig"}, the difference was consistently confirmed both in studies in which 8-OHdG levels were assessed in urine (MD: 4.43 ng/mg creatinine, 95% CI: 1.71--7.15, *p* = 0.001) and in studies using blood samples (MD: 1.42 ng/ml, 95% CI: 0.64--2.21, *p* = 0.0004). Heterogeneity among studies was statistically significant in all cases (*I*^2^ = 98%, *p* \< 0.00001 and *I*^2^ = 94%, *p* \< 0.00001, respectively) and no reduction in the overall heterogeneity was found after excluding one study at a time.

![**8-OHdG levels in CVD patients and controls.** 8-OHdG, 8-hydroxy-2-deoxyguanosine; CVD, cardiovascular disease.](fig-1){#f1}

Sensitivity analysis {#s010}
--------------------

As shown in [Table 2](#T2){ref-type="table"}, similar results were obtained when stratifying analysis according to the type of vascular disease (CAD, stroke, peripheral artery disease, and carotid atherosclerosis), different 8-OHdG measurement techniques, and study design.

###### 

[Subgroup Analysis: Stratification of the Analysis According to Different Vascular Diseases (Coronary Artery Disease, Stroke, Peripheral Artery Disease, and Carotid Atherosclerosis) (A), Different Techniques (B), and Samples (C) Used for 8-OHdG Measurement]{.smallcaps}

                                                                 *No. of studies*   *No. of patients*   *Effect size*                                                                 *Test for subgroup differences*
  -------------------------------------------------------------- ------------------ ------------------- ----------------------------------------------------------------------------- ---------------------------------
  \(A\) Different type of cardiovascular disease                                                                                                                                      
   Coronary artery disease                                       7                  351 Cases           SMD: 1.24; 95% CI: 0.47 to 2.01, *p* \< 0.002, *I*^2^: 95%, *p* \< 0.00001    χ^2^: 0.75, *p* = 0.39
                                                                                    404 Controls                                                                                       
   Noncoronary artery diseases^[a](#tf2){ref-type="table-fn"}^   7                  459 Cases           SMD: 0.83; 95% CI: 0.33 to 1.34, *p* = 0.001, *I*^2^: 91%, *p* ≤ 0.0001        
                                                                                    702 Controls                                                                                       
  \(B\) Different techniques for 8-OHdG measurement                                                                                                                                   
   ELISA                                                         11                 545 Cases           SMD: 1.09; 95% CI: 0.60 to 1.58, *p* \< 0.0001, *I*^2^: 93%, *p* \< 0.00001   χ^2^: 0.16, *p* = 0.69
                                                                                    909 Controls                                                                                       
   GC/LC-MS                                                      3                  265 Cases           SMD: 0.86; 95% CI: −0.15 to 1.87, *p* = 0.09, *I*^2^: 95%, *p* \< 0.00001      
                                                                                    197 Controls                                                                                       
  \(C\) Different study design                                                                                                                                                        
   Case--control studies                                         5                  325 Cases           SMD: 1.00; 95% CI: −0.30 to 1.71, *p* = 0.005, *I*^2^: 94%, *p* \< 0.00001    χ^2^: 0.02, *p* = 0.90
                                                                                    360 Controls                                                                                       
   Prospective studies                                           9                  485 Cases           SMD: 1.06; 95% CI: 0.48 to 1.65, *p* = 0.0004, *I*^2^: 94%, *p* \< 0.00001     
                                                                                    746 Controls                                                                                       

Including three studies on stroke, two on carotid atherosclerosis, and two on peripheral artery disease.

95% CI, 95% confidence interval; SMD, standard mean difference.

Metaregression analyses {#s011}
-----------------------

Metaregression models showed that an increasing mean age and an increasing prevalence of hypertension in the study population were associated with a lower difference in 8-OHdG levels among CVD patients and controls ([Fig. 2](#f2){ref-type="fig"}). In contrast, a higher difference in 8-OHdG levels among CVD patients and controls was found in the presence of a higher prevalence of male gender ([Fig. 2](#f2){ref-type="fig"}). All the other clinical and demographic variables tested did not influence the association between 8-OHdG and CVD ([Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}).

![**Metaregression analysis.** Clinical and demographic characteristics impacting the effect size.](fig-2){#f2}

Publication bias {#s012}
----------------

Because it is recognized that publication bias can affect the results of meta-analyses, we attempted to assess this potential bias using funnel plot analysis. Funnel plots of effect size *versus* standard error for studies evaluating levels of 8-OHdG in CVD patients and controls were rather asymmetrical, and the Egger test confirmed the presence of a significant publication bias (Egger = 0.001, [Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}). However, the adjusted analysis by means of Duval and Tweedie\'s trim and fill method confirmed differences in 8-OHdG levels among CVD patients and controls with an SMD of 1.25 (95% CI: 0.72--1.78, [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).

Discussion {#s013}
==========

This is the first meta-analysis, to our best knowledge, showing that 8-OHdG levels are higher in patients with CVD than in controls. Interestingly, these data were confirmed when separately evaluating studies, including CAD patients, and those on patients with other types of atherosclerotic processes (stroke, peripheral artery disease, and carotid atherosclerosis).

Further relevant information was derived from the metaregression analysis, showing that the association among 8-OHdG levels and CVD is largely independent of diabetes, hyperlipidemia, BMI, and smoking habit. In contrast, an increasing age significantly impacted on the effect size, with the association among 8-OHdG levels and CVD being stronger in younger subjects. Thus, 8-OHdG might represent a better marker of CVD in a young population. This might be consequent to the reduction in DNA turnover associated with aging ([@B11]). Similarly, an increasing prevalence of hypertension in the study population was associated with a lower difference in 8-OHdG levels among CVD patients and controls. This might be explained by some evidence suggesting that 8-OHdG levels are significantly higher in hypertensive subjects than normotensive controls ([@B31]). These data are in line with results of the study by Mendes *et al.* ([@B26]), showing that patients with cardiovascular risk factors have threefold higher levels of urinary 8-OHdG than controls.

We also found that gender might impact on the effect size of our meta-analysis. Indeed, the difference in 8-OHdG levels among CVD patients and controls was lower in female gender than in males. This finding is supported by some previously published data ([@B23]) suggesting that 8-OHdG levels are higher in females. In addition, the inclusion of postmenopausal women, in which the antioxidant effect of estrogens has been lost, can partially explain this finding ([@B32], [@B42]). A further potential explanation of gender differences in 8-OHdG urinary levels can be represented by the higher muscle mass of male subjects, thus leading to higher creatinine levels ([@B7], [@B43]).

Several cardiovascular risk factors, such as hypercholesterolemia, diabetes, hypertension, and atherosclerosis, are associated with an increased oxidative stress ([@B20]), which is the consequence of an imbalance between the generation of ROS and the activity of antioxidant defense system, due to endogenous or exogenous environmental factors and can induce oxidation of biological macromolecules such as proteins, lipids, and DNA ([@B39]).

Because of the high instability of ROS, the degree of oxidative stress can be better evaluated by the assessment of stable metabolites of oxidative reactions. 8-OHdG is a product of oxidative DNA damage and is widely recognized as a biomarker of the *in vivo* total systemic oxidative stress ([@B38], [@B40], [@B47]).

Oxidative stress is implicated in the pathogenesis of several diseases such as cancer, ischemia/reperfusion injury, diabetes, neurodegenerative and immunoinflammatory diseases, and atherosclerosis ([@B44]). In particular, the increase in 8-OHdG concentrations in CVD patients, secondary to ROS-mediated DNA damage, could mirror severity of the atherosclerotic process ([@B22]).

However, available studies on this issue are heterogeneous, providing contrasting results on the association among 8-OHdG levels and CVD. This meta-analysis, by pooling together 14 studies enrolling 810 CVD patients and 1106 controls, has allowed to further address this issue. Moreover, two studies by Ho *et al.* ([@B14]) and Kaya *et al.* ([@B19]), not included in the present meta-analysis because they performed the evaluation of DNA damage in DNA extracted from white blood cell and expressed the ratio between 8-OHdG and 10^6^ dG ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}), widely confirmed our results. When pooling together data from these two studies, we found higher levels of 8-OHdG in the 154 CAD patients than in the 97 controls (SMD: 1.79, 95% CI: 1.49--2.09, *p* \< 0.001, *I*^2^: 0%, *p* = 0.45). Thus, data obtained on this biological matrix confirm and strengthen findings reported on urine and blood samples.

In another study ([@B29]), also not included, patients with heart failure were divided in two groups on the basis of CAD presence. This study showed no statistical difference between patients with or without CAD. When patients were divided in four subgroups on the basis of the New York Heart Association functional classification, the difference, in terms of 8-OHdG, between patients with a more severe CAD and controls became statistically significant.

Moreover, confirming and extending the association between 8-OHdG levels and CAD, two studies showed a progressive reduction of 8-OHdG levels in CAD patients after reperfusion ([@B13], [@B28]).

Our study has some potential limitations. First, studies included in this meta-analysis have different inclusion and exclusion criteria and most of patients included in the analysis had concomitant cardiovascular risk factors and different types of CVDs. Since this meta-analysis is performed on aggregate data and some missing information is present in each study, the metaregression approach allowed for the adjustment for some (but not all) potential confounders. Thus, although results of metaregression analyses were able to refine analyses by assessing the influence of most clinical and demographic variables on the observed results, caution is necessary in overall result interpretation. However, although the absence of a multivariate analysis hampers the exclusion of a confounding effect due to other covariates potentially affecting the association among 8-OHdG levels and CVD, one of the included studies ([@B46]) showed that after adjusting for male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, and age, 8-OHdG levels were independently associated with the presence of CAD. In detail, a 0.1 ng/ml increase in 8-OHdG concentration was associated with an odds ratio of 1.318 (95% CI: 1.032--1.682, *p* = 0.027) for the presence of CAD ([@B46]).

The presence of significant heterogeneity among the studies needs to be discussed. An important source of heterogeneity could be due to the variability in laboratory methods used to evaluate 8-OHdG. A validated standard technique has not yet been identified and, as shown in [Table 1](#T1){ref-type="table"}, different techniques on different samples have been used in the included studies. In our meta-analysis, we have tried to address this issue by splitting analyses according to different techniques used for 8-OHdG measurement (ELISA or MS). While data were entirely confirmed in studies using the ELISA method, only a trend not achieving statistical significance was found in the studies in which MS techniques were used. However, the lack of a significant association in this latter group of studies could be partly explained by the relatively low number of studies (*n* = 3) using MS for the dosage of 8-OHdG levels. In addition, differences in 8-OHdG levels have been consistently confirmed both in studies performed on urine samples and in studies on blood samples. Although it was not possible to conclusively ascertain sources of heterogeneity, all results were confirmed after adjusting for the presence of publication bias.

In conclusion, 8-OHdG is significantly associated with both CAD and other types of atherosclerotic processes (stroke, peripheral artery disease, and carotid atherosclerosis). The standardization of a laboratory technique for 8-OHdG assessment, however, is still needed to allow for large prospective studies that are able to test 8-OHdG as a predictor of CVD.

Supplementary Material
======================
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